Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43724   clinical trials with a EudraCT protocol, of which   7255   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2020-001154-22
    Sponsor's Protocol Code Number:WA42380
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-03-31
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-001154-22
    A.3Full title of the trial
    Studio multicentrico, randomizzato, in doppio cieco, controllato con placebo per valutare la sicurezza e l’efficacia di Tocilizumab in pazienti affetti da polmonite grave da COVID-19
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Tocilizumab plus background therapy versus placebo plus background therapy in patients with severe COVID-19 pneumonia.
    Tocilizumab più terapia di background verso placebo più terapia di background in pazienti con polmonite grave da COVID-19
    A.4.1Sponsor's protocol code numberWA42380
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. Hoffmann-La Roche Ltd
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.1Name of organisation providing supportBARDA
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF. Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name Actemra®/ RoActemra®
    D. of the Marketing Authorisation holderRoche Registration GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code RO4877533/F03-01
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTOCILIZUMAB
    D.3.9.1CAS number 375823-41-9
    D.3.9.2Current sponsor codeRO4877533
    D.3.9.3Other descriptive nameTOCILIZUMAB
    D.3.9.4EV Substance CodeSUB20313
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Severe COVID-19 pneumonia
    Polmonite grave da COVID-19
    E.1.1.1Medical condition in easily understood language
    Severe COVID-19 pneumonia
    Polmonite grave da COVID-19
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10035737
    E.1.2Term Pneumonia viral
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective for this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of TCZ compared with placebo in combination with SOC for the treatment of severe COVID-19 pneumonia
    L’obiettivo primario di questo studio consiste nel valutare l’efficacia, la sicurezza, la farmacocinetica e la farmacodinamica di TCZ rispetto a placebo in combinazione con lo standard di cura (Standard Of Care, [SOC]) per il trattamento della polmonite grave da COVID-19
    E.2.2Secondary objectives of the trial
    "Not applicable"
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Age >= 18 years
    - Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan
    - SpO2 <= 93% or PaO2/FiO2 < 300 mmHg.
    - Età >= 18 anni
    - Pazienti ricoverati in ospedale affetti da polmonite da COVID-19 confermata secondo i criteri dell’Organizzazione Mondiale della Sanità (OMS) (inclusa una reazione a catena della polimerasi [Polymerase Chain Reaction, (PCR)] positiva di qualsiasi campione biologico, per es. prelevato dalle vie respiratorie, sangue, urine, feci, altri liquidi corporei) ed evidenziata mediante radiografia o tomografia computerizzata (TC) del torace
    - Saturazione di ossigeno dell’emoglobina presente nel sangue (SpO2) <= 93% o rapporto tra pressione parziale dell’ossigeno nel sangue / frazione di ossigeno nell’aria inspirata (Arterial Oxygen Partial Pressure to Fractional Inspired Oxygen, [PaO2/FiO2]) < 300 mmHg.
    E.4Principal exclusion criteria
    - Known severe allergic reactions to TCZ or other monoclonal antibodies
    - Active TB infection
    - Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)
    - In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
    - Have received oral anti-rejection or immunomodulatory drugs (including tocilizumab) within past 6 months
    - Pregnant or lactating women
    - Participating in other drug clinical trials (with possible exception of anti-viral trials)
    - ANC < 1000/mm3
    - Platelet count < 50,000/mm3
    - ALT or AST > 10 x ULN
    - Treatment with an investigational drug within 5 half-lives or 30 days
    - Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator’s judgment, precludes the patient’s safe participation in and completion of the study.
    - Reazioni allergiche gravi note a TCZ o altri anticorpi monoclonali
    - Sospetta infezione tubercolare (TB) attiva
    - Sospetta infezione batterica, micotica, virale o altra infezione attiva (oltre all’infezione da COVID-19)
    - Secondo l’opinione dello sperimentatore, la progressione al decesso è imminente e, pertanto, inevitabile entro le 24 ore successive, indipendentemente dalla somministrazione di trattamenti
    - Avere ricevuto farmaci antirigetto o immunomodulatori per via orale (compreso tocilizumab) negli ultimi 6 mesi
    - Donne in gravidanza o che allattano al seno
    - Partecipazione ad altre sperimentazioni cliniche di medicinali (con possibile eccezione delle sperimentazioni di farmaci antivirali)
    - Conta assoluta dei neutrofili (Absolute Neutrophil Count, [ANC]) < 1.000/mm
    - Conta piastrinica < 50.000/mm3
    Alanina aminotransferasi (ALT) o aspartato aminotransferasi (AST) > 10 volte il limite superiore della norma (Upper Limit of Normal, [ULN])
    - Trattamento con un farmaco sperimentale entro 5 emivite o 30 giorni
    - Qualsiasi condizione medica seria o anomalia ai test clinici di laboratorio che, a giudizio dello sperimentatore, precluda la partecipazione sicura allo studio e il completamento dello stesso da parte del/la paziente.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is Clinical status assessed using a 7-category ordinal scale.
    L’endpoint di efficacia primario è costituito dallo stato clinico valutato utilizzando una scala ordinale a 7 categorie.
    E.5.1.1Timepoint(s) of evaluation of this end point
    at Day 28
    Al giorno 28
    E.5.2Secondary end point(s)
    The secondary efficacy endpoints are:
    • Time to clinical improvement
    • Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status
    • Incidence of mechanical ventilation
    • Ventilator-free days
    • Organ failure-free
    • Incidence of intensive care unit (ICU) stay
    • Duration of ICU stay
    • Time to clinical failure, defined as the time to death, mechanical ventilation, ICU admission, or withdrawal
    • Mortality rate
    • Time to hospital discharge or “ready for discharge”
    • Duration of supplemental oxygen.
    Gli endpoint di efficacia secondari sono:
    • Tempo al miglioramento clinico
    • Tempo al miglioramento di almeno 2 categorie rispetto al basale su una scala ordinale a 7 categorie di valutazione dello stato clinico
    • Incidenza della ventilazione meccanica
    • Giorni senza utilizzo del ventilatore
    • Assenza di insufficienza d’organo
    • Incidenza della degenza in unità di terapia intensiva (UTI)
    • Durata della degenza in UTI
    • Tempo al fallimento clinico, definito come il tempo trascorso fino al decesso, alla ventilazione meccanica, al ricovero ospedaliero in UTI o al ritiro
    • Tasso di mortalità
    • Tempo alla dimissione dall’ospedale o alla condizione di paziente “pronto/a per la dimissione”
    • Durata della supplementazione di ossigeno.
    E.5.2.1Timepoint(s) of evaluation of this end point
    At time points throughout the study
    Ai diversi punti dello studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA35
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of this study is defined as the date when the last patient, last visit (LPLV) occurs or the date at which the last data point required for statistical analysis or safety follow-up is received from the last patient, whichever occurs later.
    In addition, the Sponsor may decide to terminate the study at any time.
    La conclusione di questo studio è definita come la data in cui si verifica l’ultima visita dell’ultimo/a paziente (Last Patient Last Visit, [LPLV]) o la data in cui si ottiene dall’ultimo/a paziente l’ultimo punto dati richiesto per l’analisi statistica o il follow-up di sicurezza, a seconda di quale evento si verifichi più tardi. Inoltre, lo sponsor potrà decidere di concludere lo studio in qualsiasi momento.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 70
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 260
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    For patients with severe/critical COVID-19 pneumonia, they may not be able to sign by themselves.
    Per i pazienti con polmonite COVID-19 grave / critica, potrebbero non essere o essere in grado di firmare da soli.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 330
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Since the tocilizumab treatment is not intended for continued therapy, the Sponsor does not have any plans to provide Roche tocilizumab or any other study treatments to patients who have completed the study. The Roche Global Policy on Continued Access to Investigational Medicinal Product is available at the following website:
    Poiché il trattamento con tocilizumab non è indicato per la terapia continua, lo sponsor non prevede di fornire tocilizumab o altri trattamenti dello studio di Roche ai pazienti che hanno completato lo studio. L’Informativa globale di Roche sull’accesso continuo al prodotto medicinale sperimentale è disponibile al seguente sito Web: http://www.roche.com/policy_continued_access_to_investigational_ medicines.pdf
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-03-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-03-30
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands